• / Free eNewsletters & Magazine
  • / My Account
Home>FDA OKs Genentech multiple-sclerosis drug Ocrevus

FDA OKs Genentech multiple-sclerosis drug Ocrevus

3party Content

Wed, 29 Mar 2017

By Thomas M. Burton Breakthrough drug treatment to cost $65,000 a year The Food and Drug Administration approved a multiple-sclerosis drug called Ocrevus, the first treatment for the most severe type of the disease, known as primary progressive MS. The medicine, from Genentech Inc., is generically

©2017 Morningstar Advisor. All right reserved.